Publication of impact on health-related quality of life from 3 year data with vosoritide. These data suggest that after 3 years of treatment, vosoritide demonstrates a…
Since the approval of vosoritide in 2021, a need was created for a treatment guideline for support clinicians. An international collaborative of leading experts and patient…
Achondroplasia is the most common skeletal dysplasia and is characterized by a variety of medical, functional and psychosocial challenges across the lifespan. There is variability in…
Despite the recognized expertise of pediatric endocrinologists, children with skeletal dysplasias have not been consistently managed by these physicians. Growth-altering treatments have broadened the role of…
Achondroplasia growth charts included in this article. Achondroplasia is the most common genetic skeletal disorder causing disproportionate short stature/dwarfism. Common additionalfeatures include spinal stenosis, midface retrusion,…